Through IPI’s industry-technology matching services, Good Pharma Dermatology collaborated with the National Skin Centre (NSC) to commercialise an over-the-counter (OTC) anti-itch moisturizer.
Good Pharma Dermatology is a Singapore pharmaceutical sales and marketing company focusing on hospital specialty and over-the-counter (OTC) medicines. It was constantly looking for opportunities to introduce new products to capture the high growth South East Asian markets through joint ventures, strategic investments and acquisitions with domestic firms and partners.
Seeking a topical agent suitable for widespread application that is clinically effective for itch relief due to dermatological diseases, there has been no such topical agent available currently in the Singapore market. Topical agents formulated for localized itch relief is not suitable for widespread use due to their irritation and allergic effects. Moreover, moisturizer-based creams which are available in the market, mainly for atopic eczema, do not provide clinically significant levels of itch relief.
IPI connected Good Pharma Dermatology to the NSC which has formulated an anti-itch moisturizer cream to treat dermatological diseases. The proprietary formulation contains both the topical agent and moisturizing cream that relieves itch and moisturizes the skin at the same time. Since 2011, NSC has treated thousands of patients with the formulation under doctor’s prescription. It has proven to be clinically effective in itch relief and is free from side effects. NSC was then seeking a partner to commercialize the formulation as an OTC product.
“Our formulation is suitable for use in almost all itchy conditions, such as various types of eczema, itchy psoriasis and kidney failure-associated itch. We decided to introduce this cream to the mass market after much positive feedbacks received from our patients and doctors,” said Dr Tey Hong Liang, Consultant and Clinician Researcher of NSC. “We think that this cream can cater to an unmet need and benefit many more people by making it available as an over-the-counter cream.”
Through IPI’s assistance, Good Pharma Dermatology was connected to NSC to discuss a licensing agreement of the proprietary formulation for topical skin application. Within five months of technical evaluation and business negotiations, both parties signed and concluded the license agreement. While the territory of the licensing agreement is global, initial product launch will be in Singapore, followed by South East Asia.
“Many people will benefit from making this product available more broadly, as it serves a very real medical need. Working with IPI’s network of partners and leveraging on their professional assistance, we have been able to quickly identify an opportunity to introduce a new product and enter into a new market at a faster pace.” said Dr John O’Shea, Medical Director at Good Pharmaceutical.
* * * * *
For more information on the developments after the licensing agreement was signed, please visit https://www.ipi-singapore.org/success-stories/formulated-in-singapore-suu-balm-sets-to-further-expand-to-overseas-markets.html
Good Pharma Dermatology sought to expand its product portfolio with clinically effective solutions that address unmet needs in the dermatological market, particularly for itch relief. At the time, there was no suitable topical agent in Singapore that could be safely and effectively used for widespread application to relieve itch caused by various dermatological diseases. Existing topical agents were formulated for localized itch relief and were not appropriate for broader use due to their potential to cause irritation and allergic reactions. Additionally, moisturizer-based creams available in the market, mainly targeting atopic eczema, did not provide clinically significant levels of itch relief. This gap left many patients with chronic skin conditions such as eczema, psoriasis, and kidney failure-associated itch without an effective, safe, and convenient over-the-counter solution. Good Pharma Dermatology recognized the opportunity to address this unmet need by introducing a novel product that could deliver both itch relief and skin moisturization, but required access to a clinically validated formulation and a partner with proven expertise in dermatological research.
IPI Singapore connected Good Pharma Dermatology to the National Skin Centre (NSC), which had developed a proprietary anti-itch moisturizer cream designed to treat dermatological diseases. By leveraging IPI’s industry-technology matching services, Good Pharma Dermatology was introduced to NSC’s clinically proven formulation that combines a topical agent with a moisturizing cream, providing effective itch relief and skin hydration simultaneously. Through IPI’s facilitation, Good Pharma Dermatology and NSC engaged in discussions to license the proprietary formulation for topical skin application. Within five months of technical evaluation and business negotiations, IPI’s support enabled both parties to sign and conclude a global license agreement. This partnership allowed Good Pharma Dermatology to commercialise the product as an over-the-counter (OTC) cream, with an initial launch in Singapore and plans for expansion into the South East Asian market.
"Our formulation is suitable for use in almost all itchy conditions, such as various types of eczema, itchy psoriasis and kidney failure-associated itch. We decided to introduce this cream to the mass market after much positive feedbacks received from our patients and doctors. We think that this cream can cater to an unmet need and benefit many more people by making it available as an over-the-counter cream."
"Many people will benefit from making this product available more broadly, as it serves a very real medical need. Working with IPI’s network of partners and leveraging on their professional assistance, we have been able to quickly identify an opportunity to introduce a new product and enter into a new market at a faster pace."
Good Pharma Dermatology is a Singapore pharmaceutical sales and marketing company focusing on hospital specialty and over-the-counter (OTC) medicines. It was constantly looking for opportunities to introduce new products to capture the high growth South East Asian markets through joint ventures, strategic investments and acquisitions with domestic firms and partners.